Merus to Present at Upcoming Investor Conferences [Yahoo! Finance]
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: Yahoo! Finance
developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: Guggenheim Securities Healthcare Innovation Conference (fireside chat): Tuesday, November 12 at 9:30 a.m. ET Stifel 2024 Healthcare Conference (fireside chat): Monday, November 18 at 3:00 p.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ® . Multiclonics ® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conve
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCGlobeNewswire
- Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy [Yahoo! Finance]Yahoo! Finance
- Merus (NASDAQ: MRUS) had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a "buy" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.MarketBeat
- Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC [Yahoo! Finance]Yahoo! Finance
MRUS
Earnings
- 8/1/24 - Miss
MRUS
Sec Filings
- 12/16/24 - Form SCHEDULE
- 12/5/24 - Form 8-K
- 12/2/24 - Form 8-K
- MRUS's page on the SEC website